LONDON, December 10, 2015 /PRNewswire/ --
DBV has now started the Phase III Viaskin Peanut trial (PEPITES), which has been enlarged to meet patient and investigator demand, a positive sign for future potential uptake. The Phase II Viaskin Milk trial (SMILEE) has also started as a potential treatment for EoE, a food allergy-related disease. The EoE trial broadens DBV's focus beyond traditional food allergy, which includes peanut, cow's milk and hen's egg allergy.
Our rNPV-based valuation is increased to $1.85bn (from $1.36bn) or $38.4/ADS owing to incorporation of the July US public offering, which raised gross proceeds of $282m, in addition to an increased probability of 65% for Viaskin Peanut to reflect the improved treatment effect observed with longer-term therapy. Our valuation does not include any contribution for Viaskin Milk in EoE.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.
About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact: Cynthia Lee Pan, +44(0)20-3077-5700
Learn more at http://www.edisongroup.com and connect with Edison on:
SOURCE Edison Investment Research